NASDAQ:CDXC - Chromadex Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$2.95 -0.12 (-3.91 %)
(As of 12/13/2018 12:37 PM ET)
Previous Close$3.07
Today's Range$2.98 - $3.1827
52-Week Range$2.79 - $6.65
Volume74,414 shs
Average Volume116,071 shs
Market Capitalization$154.29 million
P/E Ratio-8.43
Dividend YieldN/A
Beta1.37
ChromaDex Corporation operates as a nutraceutical company. The company offers research and quality control products and services to dietary supplements, food, beverages, cosmetic, and pharmaceutical industries; Nicotinamide riboside (NIAGEN), a novel form of vitamin B3 for enhancing nicotinamide adenine dinucleotide(NAD) level used for healthy aging; Pterostilbene (pTeroPure), a polyphenol and antioxidant used in health related fields; and Immulina, a spirulina extract and compound, which is used for improving human immune function, as well as developing Pterostilbene and caffeine co-crystal ingredients, and anthocyanins ingredients. It also provides reference standards, materials, and kits to conduct quality control of raw materials and consumer products; and fine chemicals and phytochemicals for research and new product development applications. In addition, the company offers a range of consulting services, including regulatory support, product development, risk management, and litigation support. Further, it assists customers in creating processes for manufacturing natural products using green chemistry, as well as developing phytochemical libraries. The company markets and sells its products directly in the United States and Canada; and through international distributors. ChromaDex Corporation has a strategic partnership for healthy aging research with the Jiangxi Provincial Government, the People's Republic of China. ChromaDex Corporation is based in Irvine, California.

Receive CDXC News and Ratings via Email

Sign-up to receive the latest news and ratings for CDXC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Medicinals & botanicals
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CDXC
Previous Symbol
CUSIPN/A
Phone949-419-0288

Debt

Debt-to-Equity Ratio0.01
Current Ratio3.20
Quick Ratio2.66

Price-To-Earnings

Trailing P/E Ratio-8.43
Forward P/E Ratio-5.00
P/E GrowthN/A

Sales & Book Value

Annual Sales$21.20 million
Price / Sales7.67
Cash FlowN/A
Price / Cash FlowN/A
Book Value$1.00 per share
Price / Book2.95

Profitability

EPS (Most Recent Fiscal Year)($0.35)
Net Income$-11,370,000.00
Net Margins-112.99%
Return on Equity-77.80%
Return on Assets-61.86%

Miscellaneous

Employees74
Outstanding Shares55,100,000
Market Cap$154.29 million
OptionableOptionable

Chromadex (NASDAQ:CDXC) Frequently Asked Questions

What is Chromadex's stock symbol?

Chromadex trades on the NASDAQ under the ticker symbol "CDXC."

How were Chromadex's earnings last quarter?

Chromadex Corp (NASDAQ:CDXC) announced its quarterly earnings data on Wednesday, November, 7th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.12) by $0.04. The firm had revenue of $8.12 million for the quarter, compared to the consensus estimate of $9 million. Chromadex had a negative net margin of 112.99% and a negative return on equity of 77.80%. View Chromadex's Earnings History.

When is Chromadex's next earnings date?

Chromadex is scheduled to release their next quarterly earnings announcement on Thursday, March 14th 2019. View Earnings Estimates for Chromadex.

What price target have analysts set for CDXC?

1 equities research analysts have issued 1-year price objectives for Chromadex's stock. Their predictions range from $6.00 to $6.00. On average, they anticipate Chromadex's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 99.3% from the stock's current price. View Analyst Price Targets for Chromadex.

What is the consensus analysts' recommendation for Chromadex?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chromadex in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Chromadex.

What are Wall Street analysts saying about Chromadex stock?

Here are some recent quotes from research analysts about Chromadex stock:
  • 1. According to Zacks Investment Research, "ChromaDex Corporation and its subsidiaries supply phytochemical reference standards and reference materials, related contract services, and products for the dietary supplement, nutraceutical, food and beverage, functional food, pharmaceutical and cosmetic markets. ChromaDex's core business strategy is to use the intellectual property harnessed by its expertise in the area of natural products and in the creation of reference materials to the industry as the basis for providing new and alternative, green, mass marketable products to its customers. The Company's main priority is to create industry-accepted information, and to provide products and services to every layer of the functional food, pharmaceutical, personal care and dietary supplement markets. The company markets and sells its products in the United States and Canada. It offers its products through distributors in Europe, South America, Korea, India, Japan, Australia, New Zealand, China, Indonesia, Malaysia, Singapore, Thailand, and Mexico. " (11/15/2018)
  • 2. HC Wainwright analysts commented, "Valuation methodology, risks and uncertainties. We apply a 24x EV- to-EBITDA multiple to 2020 EBITDA per share of $0.45, discounted back at 12%, which yields a price objective of approximately $8.00 per share." (9/10/2018)

Has Chromadex been receiving favorable news coverage?

Media coverage about CDXC stock has trended somewhat positive recently, InfoTrie reports. The research firm ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Chromadex earned a news sentiment score of 2.0 on InfoTrie's scale. They also gave news stories about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the next several days.

Who are some of Chromadex's key competitors?

Who are Chromadex's key executives?

Chromadex's management team includes the folowing people:
  • Mr. Frank Louis Jaksch Jr., Co-Founder & Exec. Chairman (Age 50)
  • Mr. Robert N. Fried, CEO & Director (Age 58)
  • Mr. Kevin M. Farr, Chief Financial Officer (Age 60)
  • Mr. Troy Allen Rhonemus, Exec. VP (Age 45)
  • Dr. Matthew Roberts, Chief Scientific Officer, Sr. VP of Innovation & Member of Scientific Advisory Board

Who are Chromadex's major shareholders?

Chromadex's stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (3.48%), Vanguard Group Inc. (2.85%), Tieton Capital Management LLC (1.96%), Citadel Advisors LLC (0.08%), Wells Fargo & Company MN (0.07%) and North Star Investment Management Corp. (0.07%). Company insiders that own Chromadex stock include Frank L Jaksch Jr, Kevin M Farr, Mark J Friedman, River Ventures Ltd Champion, Robert N Fried, Step Holdings Ltd Pioneer and Stephen R Allen. View Institutional Ownership Trends for Chromadex.

Which institutional investors are selling Chromadex stock?

CDXC stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN and North Star Investment Management Corp.. View Insider Buying and Selling for Chromadex.

Which institutional investors are buying Chromadex stock?

CDXC stock was purchased by a variety of institutional investors in the last quarter, including Tieton Capital Management LLC, Vanguard Group Inc., BlackRock Inc. and Citadel Advisors LLC. Company insiders that have bought Chromadex stock in the last two years include Frank L Jaksch Jr, Kevin M Farr, Mark J Friedman, River Ventures Ltd Champion, Robert N Fried, Step Holdings Ltd Pioneer and Stephen R Allen. View Insider Buying and Selling for Chromadex.

How do I buy shares of Chromadex?

Shares of CDXC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Chromadex's stock price today?

One share of CDXC stock can currently be purchased for approximately $3.01.

How big of a company is Chromadex?

Chromadex has a market capitalization of $154.29 million and generates $21.20 million in revenue each year. The company earns $-11,370,000.00 in net income (profit) each year or ($0.35) on an earnings per share basis. Chromadex employs 74 workers across the globe.

What is Chromadex's official website?

The official website for Chromadex is http://www.chromadex.com.

How can I contact Chromadex?

Chromadex's mailing address is 10005 Muirlands Blvd. Suite G, IRVINE CA, 92618. The company can be reached via phone at 949-419-0288 or via email at [email protected]


MarketBeat Community Rating for Chromadex (NASDAQ CDXC)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  234 (Vote Outperform)
Underperform Votes:  221 (Vote Underperform)
Total Votes:  455
MarketBeat's community ratings are surveys of what our community members think about Chromadex and other stocks. Vote "Outperform" if you believe CDXC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CDXC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/13/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel